E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Virus Diseases [C02] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 23.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10051905 |
E.1.2 | Term | Coronavirus infection |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Assess the efficacy of favipiravir in addition to standard care in patients with COVID-19 in reducing the severity of disease compared to standard care alone |
|
E.2.2 | Secondary objectives of the trial |
(1) Assess the effect of favipiravir in addition to standard care in the study population compared to standard care alone. (2) Evaluate the safety and tolerability of favipiravir in the study population |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
(1) Age 16 or over at time of consent (2) Exhibiting symptoms associated with COVID-19 (3) Positive for SARS-CoV-2 on valid COVID-19 test (4) Point 1, 2, 3, or 4 on the WHO COVID-19 ordinal severity scale at time of randomisation. (Asymptomatic with postiviepositive COVID19 test, Symptomatic Independent, Symptomatic assistance needed, Hospitalized, with no oxygen therapy) (5) Have >=10% risk of death should they be admitted to hospital as defined by the ISARIC4C risk index: https://isaric4c.net/risk (6) Able to provide written informed consent (7) Negative pregnancy test (women of childbearing potential*) (8) Able to swallow oral medication
|
|
E.4 | Principal exclusion criteria |
(1) Renal impairment requiring dialysis or haemofiltration (2) Pregnant or breastfeeding (3) Of child bearing potential* (women), or with female partners of child bearing potential (men) who do not agree to use adequate contraceptive measures for the duration of the study and for 3 months after the completion of study treatment (4) History of hereditary xanthinuria (5) Xanthine urinary calculi (6) Other patients judged ineligibleunsuitable by the Principal Investigator or sub-Investigator (7) Known hypersensitivity to favipiravir, its metabolites or any excipients (8) Severe co-morbidities including : patients with severe hepatic impairment defined as: • (greater than Child-Pugh grade A- see (Appendix 4) • AST or ALT > 5 x ULN • AST or ALT > 3x ULN and Total Bilirubin >2xULN) (9) More than 96 hours since swabfirst positive for COVID19 PCRtest was taken. (10) Unable to discontinue contra-indicated concomitant medications (section 6.7)
* Non-childbearing potential must be evidenced by fulfilling one of the following criteria at screening: • Post-menopausal defined as aged more than 50 years and amenorrhoeic for at least 12 months following cessation of all exogenous hormonal treatments. • Documentation of Iirreversible surgical sterilisation by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
(1) Assess the efficacy of favipiravir in addition to standard care in patients with COVID-19 in reducing the severity of disease compared to standard care alone |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Clinical status as assessed by WHO COVID 10 point ordinal severity scale at day 15 |
|
E.5.2 | Secondary end point(s) |
(1) Assess the effect of favipiravir in addition to standard care in the study population compared to standard care alone (2) Evaluate the safety and tolerability of favipiravir in the study population
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
(1) (a) Proportion of patients meeting level 7 or above on the WHO COVID 10 point ordinal severity scale or dead by day 29 (b) WHO COVID 10 point ordinal severity scale level - days 8, 29, 60 (c) Overall survival - up to and including day 60 (d) In patients only - viral clearance on or before day 8 of treatment - day 8 (e) In patients only - duration of pyrexia in days (define by temperature > 38 degrees C - up to and including day 60
(2) Adverse events - up to and including day 60
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of trial is defined when the Trial Steering Committee agrees that one or more of the following situations apply: • Six months after the last patient is recruited • Final follow-up visit of the last patient • The stated objectives of the trial are achieved.
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 1 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 1 |